Former Republican Nebraska Sen. Ben Sasse revealed his dying wish for America during a Sunday interview with CBS News.
Sasse, who is suffering from terminal pancreatic cancer, told “60 Minutes” that he wants more Americans to “break bread” together and figure out how to serve the next generation. The former senator is undergoing treatment for stage 4 cancer and has already surpassed his life expectancy.
“I think we need to have more deliberation about our mortality and our finitude to therefore get back to wisdom about what living a life of gratitude looks like. And I’d like a lot more dinner tables to turn off the devices, put them out of the room, pour a big glass of wine, break bread together and wrestle with some really grand questions about what you’re building for your family and your next generation,” Sasse said.
WATCH:
Sasse announced his diagnosis in December and stated that his illness was a “death sentence.” He is taking Revolution Medicine’s daraxonrasib, which he referred to as a “miracle drug.” Doctors gave Sasse three or four months to live, though the drug has extended his time to live.
“I have much, much less pain than I did four months ago when I was diagnosed. And I have a massive 76% reduction in tumor volume over the last four months. So maybe I’ll live a year instead of a handful of months and I feel incredibly blessed,” Sasse said.
Sasse also said that he is both optimistic and pessimistic about the U.S.’ future.
The former senator served eight years in the Senate after first being elected in 2014. He was one of seven Republican senators who voted to convict President Donald Trump during his second impeachment trial regarding the Jan. 6, 2021, Capitol riot.
Sasse resigned from Congress in January 2023 to become the president of the University of Florida.
All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact [email protected].
